Emollient cream with a milk-derived peptide for children with mild atopic dermatitis
Official title: Effect of Glycomacropeptide on Clinical Manifestations of Atopic Dermatitis in Children: a Pilot Study
Run by Universidad Autónoma de Aguascalientes · NCT07259343 · Data updated 2026-11-12
This trial will see if an emollient cream containing a milk peptide (glycomacropeptide) can reduce itch, skin signs, and Staphylococcus colonization in children aged 2–12 with mild atopic dermatitis compared with a regular emollient.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 2 Years to 12 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Universidad Autónoma de Aguascalientes Academic / other |
| Locations | 1 site (Aguascalientes, Aguascalientes) |
| Status | Recruiting |
| Started | September 26, 2025 |
| Main results expected | January 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | December 2, 2025 |
| Trial ID | NCT07259343 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 2–12 years with a clinical diagnosis of atopic dermatitis by Hanifin and Rajka criteria, SCORAD under 25, and parental consent are the intended participants.
✕Probably not a fit
Children with moderate-to-severe atopic dermatitis (SCORAD >25), other active skin diseases, or known allergy to the cream components are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Children aged 2–12 with mild atopic dermatitis (SCORAD <25) will be enrolled and receive either an emollient cream containing glycomacropeptide or the same emollient without the peptide, and outcomes will be compared between groups. Clinical severity scores and pruritus will be measured alongside skin cultures to quantify Staphylococcus colonization. The intervention is topical and used as an additive to standard emollient care, with parental consent required for participation. Exclusion criteria include moderate-to-severe AD, other dermatoses, known hypersensitivity to cream components, or inability to attend follow-up visits.
Why it matters
Potential benefit: If successful, the peptide-containing emollient could reduce itch and visible eczema and lower bacterial colonization, offering a gentler topical option for children with mild AD.
How similar studies have gone: Topical use of glycomacropeptide for atopic dermatitis is relatively novel with limited prior clinical data, though related approaches using barrier-supporting or antimicrobial peptides have shown mixed or preliminary benefits.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children aged between 2 and 12 years. * Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka criteria. * Mild atopic dermatitis with SCORAD \<25 points. * Written informed consent signed by parents or legal guardian. Exclusion Criteria: * Age younger than 2 years or older than 12 years. * Moderate to severe atopic dermatitis (SCORAD \>25 points). * Presence of other dermatoses in addition to atopic dermatitis. * Background of hypersensitivity or anaphylaxis to any components of the vehicle cream. * Allergy or hypersensitivity to glycomacropeptide. * Inability to attend follow-up medical consultations or to adhere to the treatment schedule. * Any clinical reason determined by the clinical investigator that makes the child unsuitable for the study.
Where it's running
-
Universidad Autónoma de Aguascalientes
Aguascalientes, Aguascalientes, Mexico Recruiting
Study contacts
- Principal investigator: Eva M Salinas, PhD — Universidad Autónoma de Aguascalientes
- Study coordinator: Eva M Salinas Miralles, PhD in medicine
- Email: maria.salinas@edu.uaa.mx
- Phone: 52 449-910-8424
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults
A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.
-
LT-002-158 tablets for moderate-to-severe atopic dermatitis in adults
This study tests LT-002-158 vs placebo to see if it helps adults with moderate-to-severe atopic dermatitis.
-
PRA-216 for moderate to severe atopic dermatitis: safety and how it works in the body
This study tests PRA-216 versus placebo to see if it is safe and helps people with moderate to severe atopic dermatitis.
-
Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy
This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.
-
Global Health Look at Atopic Dermatitis
A worldwide, multicenter study tests how people with atopic dermatitis access care and treat it, using data from routine medical records.
-
Stapokibart Injection for atopic dermatitis in adults
This study tests Stapokibart Injection in adults with atopic dermatitis to see how safe it is and whether it helps.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.